Phosphodiesterase 4 Inhibition Dose Dependently Stabilizes Microvascular Barrier Functions and Microcirculation in a Rodent Model of Polymicrobial Sepsis

ABSTRACTBackgroundBreakdown of microvascular endothelial barrier functions contributes to disturbed microcirculation, organ failure, and death in sepsis. Increased endothelial cAMP levels by systemic application of phosphodiesterase 4 inhibitors (PD-4-I) have previously been demonstrated to protect...

Full description

Saved in:
Bibliographic Details
Published in:Shock (Augusta, Ga.) Ga.), 2014-06, Vol.41 (6), p.537-545
Main Authors: Flemming, Sven, Schlegel, Nicolas, Wunder, Christian, Meir, Michael, Baar, Wolfgang, Wollborn, Jakob, Roewer, Norbert, Germer, Christoph-Thomas, Schick, Martin Alexander
Format: Article
Language:English
Subjects:
Animals
Coinfection - drug therapy
Disease Models, Animal
Dose-Response Relationship, Drug
Endothelium - drug effects
Hemodynamics
Male
Microcirculation - drug effects
Phosphodiesterase 4 Inhibitors - pharmacology
Rats
Rats, Sprague-Dawley
Rolipram - pharmacology
Sepsis - drug therapy
Sepsis - physiopathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACTBackgroundBreakdown of microvascular endothelial barrier functions contributes to disturbed microcirculation, organ failure, and death in sepsis. Increased endothelial cAMP levels by systemic application of phosphodiesterase 4 inhibitors (PD-4-I) have previously been demonstrated to protect microvascular barrier properties in a model of systemic inflammation (systemic inflammatory response syndrome) suggesting a novel therapeutic option to overcome this problem. However, in a clinically relevant model of polymicrobial sepsis long-term effects, immunomodulatory effects and effectivity of PD-4-I to stabilize microvascular barrier functions and microcirculation remained unexplored. MethodsWe induced polymicrobial sepsis using the colon ascendens stent peritonitis (CASP) model in which we performed macrohemodynamic and microhemodynamic monitoring with and without systemic intravenous application of different doses of PD-4-I rolipram in Sprague-Dawley rats over 26 h. ResultsAll animals with CASP showed clinical and laboratory signs of sepsis and peritonitis. Whereas macrohemodynamic adverse effects were not evident, application of PD-4-I led to stabilization of endothelial barrier properties as revealed by reduced extravasation of fluorescein isothiocyanate–albumin. However, only low-dose application of 1 mg/kg body weight per hour of PD-4-I improved microcirculatory flow in the CASP model, whereas high-dose therapy of 3 mg/kg BW per hour PDI-4-I had adverse effects. Accordingly, sepsis-induced acute kidney injury and lung edema were prevented by PD-4-I treatment. Furthermore, PD-4-I showed immunomodulatory effects as revealed by decreased interleukin 1α (IL-1α), IL-1β, IL-12, and tumor necrosis factor α levels following PD-4-I treatment, which appeared not to correlate with barrier-stabilizing effects of rolipram. ConclusionsThese data provide further evidence that systemic application of PD-4-I could be suitable for therapeutic microvascular barrier stabilization and improvement of microcirculatory flow in sepsis.
ISSN:1073-2322
1540-0514
DOI:10.1097/SHK.0000000000000152